Zenyth Therapeutics

In 2001, CAT and Zenyth (formally Amrad) (http://www.zenyth.com.au) (acquired by CSL in 2006) entered into a product collaboration for the joint discovery and development of human monoclonal antibody therapeutics that neutralise the GM-CSF Receptor (granulocyte-macrophage colony stimulating factor) which may play a central role in the development of chronic inflammatory diseases including rheumatoid arthritis.

CAT and Zenyth will jointly fund all development through to completion of Phase II proof-of-concept studies. CAT has the primary responsibility for further development and commercialisation of human monoclonal antibody drug candidates arising from the agreement and Zenyth will have the option to receive milestone payments during the completion of development and royalty payments on sales from CAT, or to participate jointly with CAT in further development and commercialisation.

Zenyth is contributing its intellectual property and know-how in relation to the therapeutic target, pre-clinical and development capabilities and CAT is contributing its antibody libraries, high-throughput functional screening, pre-clinical and development capabilities.